Home >> Research Area >> Proteases/Proteasome

Proteases/Proteasome

Proteasomes are protein complexes inside all eukaryotes and archaea, and in some bacteria. In eukaryotes, proteasomes are located in the nucleus and the cytoplasm. The main function of the proteasome is to degrade unneeded or damaged proteins by proteolysis, a chemical reaction that breaks peptide bonds. Enzymes that help such reactions are called proteases. Proteasomes are part of a major mechanism by which cells regulate the concentration of particular proteins and degrade misfolded proteins. The degradation process yields peptides of about seven to eight amino acids long, which can then be further degraded into shorter amino acid sequences and used in synthesizing new proteins. Proteins are tagged for degradation with a small protein called ubiquitin. The tagging reaction is catalyzed by enzymes called ubiquitin ligases. Once a protein is tagged with a single ubiquitin molecule, this is a signal to other ligases to attach additional ubiquitin molecules. The result is a polyubiquitin chain that is bound by the proteasome, allowing it to degrade the tagged protein. NF-

Products for Proteases/Proteasome

  1. Cat.No. Product Name Information
  2. BCC1218 Pepstatin A Pepstatin (Pepstatin A) is a specific aspartic protease inhibitor produced by actinomycetes, with IC50s of 4.5 nM, 6.2 nM, 150 nM, 290 nM, 520 nM and 260 nM for hemoglobin-pepsin, hemoglobin-proctase, casein-pepsin, casein-proctase, casein-acid protease and hemoglobin-acid protease, respectively. Pepstatin Ammonium also inhibits HIV protease. Pepstatin A
  3. BCC3648 VX-765 Belnacasan (VX-765) is an orally bioactive prodrug of VRT-043198, which is a potent and selective inhibitor of IL-converting enzyme (ICE)/caspase-1 with Kis of 0.8 nM and less than 0.6 nM for caspase-1 and caspase-4, respectively. Belnacasan (VX-765) inhibits the release of LPS-induced IL-1β and IL-18 by human PBMCs with an IC50 of ~0.7 μM. VX-765
  4. BCC2112 Vildagliptin (LAF-237) Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity. Vildagliptin (LAF-237)
  5. BCC7676 Gedunin Gedunin
  6. BCC2340 BMS 299897 BMS 299897 is a sulfonamide γ-secretase inhibitor with an IC50 of 7 nM for Aβ production inhibition in HEK293 cells stably overexpressing amyloid precursor protein (APP). BMS 299897
  7. BCC2344 L-685,458 L-685458 is a potent inhibitor of Amyloid β-Protein precursor γ-secretase activity with IC50 of 17 nM, shows greater than 50-100-fold selectivity over other aspartyl proteases tested. L-685,458
  8. BCC2361 L 006235 Potent cathepsin K inhibitor L 006235
  9. BCC1482 Ciluprevir (BILN-2061) Ciluprevir (BILN-2061)
  10. BCC2125 Geldanamycin Selective Hsp90 inhibitor; breast cancer stem cell inhibitor,Geldanamycin is a natural existing HSP90 inhibitor with Kd of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association. Geldanamycin
  11. BCC2372 CL 82198 hydrochloride CL-82198 is a selective inhibitor of MMP-13. CL-82198 binds to the entire S1’ pocket of MMP-13, which is the basis for its selectivity towards MMP-13 and the lack of inhibitory activities against other MMPs. CL-82198 is a pharmacologic treatment for preventing osteoarthritis (OA) progression. CL 82198 hydrochloride
  12. BCC2380 WAY 170523 WAY 170523
  13. BCC1219 AEBSF.HCl AEBSF hydrochloride is an irreversible inhibitor of serine proteases, such as chymotrypsin, kallikrein, plasmin, thrombin, and trypsin. AEBSF.HCl
  14. BCC2086 IU1 IU1 is a special Usp14 inhibitor with an IC50 of 4-5 μM. IU1
  15. BCC1229 PMSF PMSF is an irreversible serine/cysteine protease inhibitor commonly used in the preparation of cell lysates. PMSF
  16. BCC2369 SSR 69071 SSR 69071
  17. BCC3934 Saxagliptin Saxagliptin is an orally active dipeptidyl peptidase-4 (DPP4) inhibitor that helps control blood sugar levels. Saxagliptin
  18. BCC1435 Boceprevir Boceprevir is a novel, potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with Ki of 14 nM in both enzyme assay and EC90 of 350 nM in cell-based replicon assay. Boceprevir
  19. BCC2107 Telaprevir (VX-950) Telaprevir is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (Ki) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide. Telaprevir (VX-950)
  20. BCC2348 SC 57461A Selective inhibitor of LTA4 hydrolase SC 57461A
  21. BCC1512 Dabigatran ethyl ester Dabigatran ethyl ester is an emerging oral anticoagulant which is a direct inhibitor of thrombin activity. Dabigatran ethyl ester
  22. BCC3598 Cathepsin G Inhibitor I Cathepsin G Inhibitor I
  23. BCC2364 K 579 Dipeptidyl peptidase IV (DPP-IV) inhibitor K 579
  24. BCC1365 Anguizole Anguizole is a small molecule inhibitor of HCV replication and alters NS4B's subcellular distribution. Anguizole
  25. BCC2381 BC 11 hydrobromide Selective urokinase (uPA) inhibitor BC 11 hydrobromide
  26. BCC1346 Alvespimycin Alvespimycin (17-DMAG) is a potent inhibitor of Hsp90, binding to Hsp90 with an EC50 of 62 ± 29 nM. Alvespimycin
  27. BCC2090 MK-0752 MK-0752 is a moderately potent γ-secretase inhibitor, which reduces Aβ40 production with IC50 of 5 nM. MK-0752
  28. BCC1543 Edoxaban Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention. Edoxaban is a also weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10 000-fold selectivity for FXa. Edoxaban has antithrombotic properties and has potential for thromboembolic diseases treatment. Edoxaban
  29. BCC1544 Edoxaban tosylate Edoxaban tosylate (DU-176b) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban tosylate is an anticoagulant agent and can be used for stroke prevention. Edoxaban tosylate is a also weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10 000-fold selectivity for FXa. Edoxaban tosylate has antithrombotic properties and has potential for thromboembolic diseases treatment. Edoxaban tosylate
  30. BCC2337 Elesclomol (STA-4783) Elesclomol is an oxidative stress inducer that induces cancer cell apoptosis. Elesclomol (STA-4783)
  31. BCC6488 DC_AC50 DC_AC50
  32. BCC2295 Apixaban Apixaban (BMS-562247-01) is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively. Apixaban is in development for the prevention and treatment of various thromboembolic diseases. Apixaban
  33. BCC2135 Fluorouracil (Adrucil) 5-Fluorouracil (5-FU) is an analogue of uracil and a potent antitumor agent. 5-Fluorouracil affects pyrimidine synthesis by inhibiting thymidylate synthetase thus depleting intracellular dTTP pools. 5-Fluorouracil induces apoptosis and can be used as a chemical sensitizer. 5-Fluorouracil also inhibits HIV. Fluorouracil (Adrucil)
  34. BCC2342 Flurizan Tarenflurbil ((R)-Flurbiprofen) is the R-enantiomer of the racemate NSAID Flurbiprofen, Tarenflurbil ((R)-Flurbiprofen) inhibits the binding of [3H]9-cis-RA to RXRα LBD with IC50 of 75 μM. Flurizan
  35. BCC2137 Raltegravir (MK-0518) Raltegravir is a potent integrase (IN) inhibitor, used to treat HIV infection. Raltegravir (MK-0518)
  36. BCC1230 Vicriviroc Malate Vicriviroc Malate
  37. BCC1618 HIV-1 integrase inhibitor HIV-1 integrase inhibitor is uesful for anti-HIV. HIV-1 integrase inhibitor
  38. BCC1221 Bestatin Bestatin is a natural, broad-spectrum, and competitive aminopeptidase inhibitor. Bestatin
  39. BCC1197 Odanacatib (MK-0822) Odanacatib (MK-0822) is a potent and selective inhibitor of cathepsin K, with an IC50 of 0.2 nM for human cathepsin K. Odanacatib (MK-0822)
  40. BCC2343 JLK 6 JLK 6
  41. BCC1374 Asunaprevir (BMS-650032) Asunaprevir (BMS-650032) is a potent and orally bioavailable hepatitis C virus (HCV) NS3 protease inhibitor, with IC50 of 0.2 nM-3.5 nM. Asunaprevir (BMS-650032)
  42. BCC1952 SJB2-043 SJB2-043 is an inhibitor of the native USP1/UAF1 complex with IC50 of 544 nM. SJB2-043
  43. BCC5627 Darunavir Ethanolate Darunavir ethanolate (TMC114 Ethanolate) is a potent HIV protease inhibitor used to treat and prevent HIV/AIDS. Darunavir has a Ki of 1 nM for wild type HIV-1 protease. Darunavir Ethanolate
  44. BCC3908 Bestatin hydrochloride Bestatin hydrochloride is an inhibitor of CD13 (Aminopeptidase N)/APN and leukotriene A4 hydrolase, used for cancer treatment. Bestatin hydrochloride
  45. BCC2111 Sitagliptin phosphate monohydrate Sitagliptin phosphate monohydrate is a potent inhibitor of DPP4 with IC50 of 19 nM in Caco-2 cell extracts. Sitagliptin phosphate monohydrate
  46. BCC1222 E-64 E-64 (Proteinase inhibitor E 64) is a potent irreversible inhibitor against general cysteine proteases with IC50 of 9 nM for papain. E-64
  47. BCC2110 Linagliptin (BI-1356) Linagliptin is a highly potent, selective DPP-4 inhibitor with IC50 of 1 nM. Linagliptin (BI-1356)
  48. BCC2087 LDN 57444 LDN-57444 is a reversible, competitive and site-directed inhibitor of ubiquitin C-terminal hydrolase L1 (UCH-L1), with an IC50 of 0.88 μM and a Ki of 0.40 μM; LDN-57444 also suppresses UCH-L3 activity, with an IC50 of 25 μM. LDN 57444
  49. BCC6269 Hexa-D-arginine Hexa-D-arginine (Furin Inhibitor II) is a stable furin inhibitor with Ki values 106 nM, 580 nM and 13.2 μM for furin, PACE4 and prohormone convertase-1 (PC1), respectively. Hexa-D-arginine blocks Pseudomonas exotoxin A and anthrax toxins toxicity in vitro and in vivo. Hexa-D-arginine
  50. BCC2345 MRK 560 MRK-560 is a potent, orally bioavailable and brain-penetrant γ-secretase inhibitor. MRK 560
  51. BCC1396 Balapiravir Balapiravir (R1626, Ro 4588161) is the prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase (R1479, RG1479). Balapiravir
  52. BCC1796 Nesbuvir Nesbuvir is a nonnucleoside inhibitor of the hepatitis C virus (HCV) nonstructural protein 5B (NS5B) polymerase. Nesbuvir
  53. BCC2134 Elvitegravir (GS-9137) Elvitegravir (GS-9137; JTK-303; D06677) is an HIV integrase inhibitor for HIV-1IIIB, HIV-2EHO and HIV-2ROD with IC50 of 0.7 nM, 2.8 nM and 1.4 nM, respectively. Elvitegravir (GS-9137)
  54. BCC6340 UAMC 00039 dihydrochloride UAMC00039 dihydrochloride is a potent, reversible and competitive dipeptidyl peptidase II inhibitor with an IC50 of 0.48 nM. UAMC 00039 dihydrochloride
  55. BCC1427 BMS-626529 Temsavir (BMS-626529) is a novel attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4+ T cells. BMS-626529
  56. BCC2370 ARP 100 ARP-100 is a potent and selective matrix metalloproteinase MMP-2 inhibitor (IC50=12 nM). ARP-100 interacts with S1' pocket of MMP-2 and shows anti-invasive properties in an in vitro model of invasion on matrigel. ARP-100 shows the less inhibitory activity towards MMP-1 (>50 μM), MMP-3 (4.5 μM), MMP-7 (>50 μM), and MMP-9 (0.2 μM). ARP 100
  57. BCC2355 ZJ 43 ZJ 43
  58. BCC2133 BMS-707035 BMS-707035 is an HIV-1 integrase (IN) inhibitor with an IC50 value of 15 nM. BMS-707035
  59. BCC7551 Macbecin I Macbecin I
  60. BCC2123 AUY922 (NVP-AUY922) Luminespib (NVP-AUY922) is a potent HSP90 inhibitor with IC50s of 7.8 and 21 nM for HSP90α and HSP90β, respectively. AUY922 (NVP-AUY922)
  61. BCC2120 NSC 405020 NSC 405020 is a novel small molecule inhibitor of MT1-MMP that specifically targets PEX domain rather than the catalytic domain of MT1-MMP with IC50 >100 μM and does not inhibit the catalytic activity of MT1-MMP or MMP-2. NSC 405020
  62. BCC2121 17-AAG (KOS953) Tanespimycin (17-AAG) is a potent HSP90 inhibitor with an IC50 of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90. Tanespimycin (17-AAG) depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin (17-AAG) also downregulates the stk38 gene expression. 17-AAG (KOS953)
  63. BCC3588 E-64-c E 64c is a derivative of naturally occurring epoxide inhibitor of cysteine proteases, a Calcium-activated neutral protease (CANP) inhibitor and a very weak irreversible cathepsin C inhibitor. E-64-c
  64. BCC2346 Begacestat Begacestat (GSI-953) is a selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase (IC50Aβ40=15 nM) for the treatment of Alzheimer's disease. Begacestat
  65. BCC7457 Cilastatin sodium Cilastatin sodium
  66. BCC1870 PSI-6130 PSI-6130 is a potent and selective inhibitor of HCV NS5B polymerase, and inhibits HCV replication with a mean IC50 of 0.6 μM. PSI-6130
  67. BCC5229 Zofenopril calcium Zofenopril Calcium (SQ26991) is an antioxidant that acts as an angiotensin-converting enzyme inhibitor. Zofenopril calcium
  68. BCC2127 KW-2478 KW-2478 is an inhibitor of Hsp90α, with an IC50 of 3.8 nM, and has antitumor activity against various human hematological tumor cells. KW-2478
  69. BCC1228 Nafamostat Mesylate(FUT-175) Nafamostat mesylate, a synthetic serine protease inhibitor, is an anticoagulant. Nafamostat mesylate supresses T cell auto-reactivity by decreasing granzyme activity and CTL cytolysis. Nafamostat Mesylate(FUT-175)
  70. BCC5009 Enalaprilat Dihydrate Enalaprilat dihydrate (MK-422) is an angiotensin-converting enzyme (ACE) inhibitor with IC50 of 1.94 nM. Enalaprilat Dihydrate
  71. BCC2129 NVP-BEP800 VER-82576 (NVP-BEP800) is a potent, orally available and selective Hsp90 inhibitor, with an IC50 of 58 nM for Hsp90β; VER-82576 also slightly blocks Grp94 and Trap-1, with IC50s of 4.1 and 5.5 μM, respectively. NVP-BEP800
  72. BCC2089 RO4929097 RO4929097 (RG-4733) is a γ secretase inhibitor with IC50 of 4 nM, inhibiting cellular processing of Aβ40 and Notch with EC50 of 14 nM and 5 nM, respectively. RO4929097
  73. BCC4058 Alvelestat Alvelestat (AZD9668) is an orally bioavailable, affinity and selective inhibitor of neutrophil elastase (NE) with a pIC50 value of 7.9 nM, a Ki value of 9.4 nM and a Kd value of 9.5 nM. Alvelestat
  74. BCC2124 BIIB021 BIIB021 is an orally available, fully synthetic inhibitor of HSP90 with Ki and EC50 of 1.7 nM and 38 nM, respectively. BIIB021
  75. BCC2371 ARP 101 Inhibitor of MMP-2 ARP 101
  76. BCC2113 Alogliptin (SYR-322) Alogliptin (SYR-322 free base) is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9. Alogliptin (SYR-322)
  77. BCC1341 Alogliptin Benzoate Alogliptin benzoate(SYR 322) is a potent, selective inhibitor of DPP-4 with IC50 of <10 nM, exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9. Alogliptin Benzoate
  78. BCC2106 Danoprevir (RG7227) Danoprevir (ITMN-191) is an orally active NS3/4A protease inhibitor for hepatitis C virus (HCV) with an IC50 of 0.29 nM and is selective for NS3/4A over a panel of 53 proteases (IC50 higher than 10 μM). Danoprevir (ITMN-191) inhibits HCV genotypes 1a, 1b, 4, 5, and 6 (IC50s=0.2-0.4 nM) as well as 2b and 3a (IC50s=1.6, 3.5 nM). Danoprevir (RG7227)
  79. BCC1889 Retaspimycin Retaspimycin is a potent and water-soluble inhibitor of Hsp90, with EC50s of 119 nM for both Hsp90 and Grp9. Retaspimycin
  80. BCC2126 IPI-504 (Retaspimycin hydrochloride) Retaspimycin Hydrochloride is a potent and water-soluble inhibitor of Hsp90 with EC50s of 119 nM for both Hsp90 and Grp9. IPI-504 (Retaspimycin hydrochloride)
  81. BCC2367 Vialinin A Inhibitor of USP4 and USP5/IsoT Vialinin A
  82. BCC3609 PSI-6206 PSI-6206 (RO 2433) is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 low potently inhibits HCV replicon with EC90 of >100 μM. PSI-6206
  83. BCC1785 Narlaprevir Narlaprevir is a potent, selective, orally bioavailable NS3 protease inhibitor(Ki=6 nM; EC90=40 nM) Narlaprevir
  84. BCC1313 5-R-Rivaroxaban 5-R-Rivaroxaban is (R)-enantiomer of Rivaroxaban. Rivaroxaban (BAY 59-7939) is a highly potent and selective, direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM). 5-R-Rivaroxaban
  85. BCC2014 Trelagliptin Trelagliptin(SYR-472) is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor that is being developed for the treatment of type 2 diabetes (T2D). Trelagliptin
  86. BCC1848 PF-03084014 PF-03084014
  87. BCC2363 DPPI 1c hydrochloride DPPI 1c hydrochloride
  88. BCC7968 TRC 051384 TRC051384 is a heat shock protein 70 (HSP70) inducer. TRC 051384
  89. BCC2136 MK-2048 MK-2048 is a potent inhibitor of integrase and INR263K with IC50 of 2.6 nM and 1.5 nM, respectively. MK-2048
  90. BCC1540 E 2012 E 2012 is a potent gamma (γ) secretase modulator without affecting Notch processing. E 2012 inhibits 3β-hydroxysterol Δ24-reductase (DHCR24) at the final step in the cholesterol biosynthesis. E 2012 aims at Alzheimer's disease by reduction of amyloid β-42, and induces cataract following repeated doses in the rat. E 2012
  91. BCC1511 Dabigatran etexilate mesylate Dabigatran etexilate mesylate (BIBR 1048MS) is an orally active prodrug of Dabigatran. Dabigatran etexilate mesylate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation. Dabigatran etexilate mesylate
  92. BCC5012 Ramipril Ramipril (HOE-498) is an angiotensin-converting enzyme (ACE) inhibitor with IC50 of 5 nM. Ramipril
  93. BCC1872 PU-H71 PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1. PU-H71
  94. BCC1904 RO-9187 RO-9187 is a potent inhibitor of HCV virus replication with an IC50 of 171 nM. RO-9187
  95. BCC5275 Trandolapril Trandolapril (RU44570) is a nonsulfhydryl prodrug that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI). Trandolapril
  96. BCC2352 MDL 28170 MDL-28170 (Calpain Inhibitor III) is a potent, selective and membrane-permeable cysteine protease inhibitor of calpain that rapidly penetrates the blood-brain barrier following systemic administration. MDL-28170 also block γ-secretase. MDL 28170
  97. BCC1287 P005091 P005091 is a selective and potent inhibitor of ubiquitin-specific protease 7 (USP7) with an EC50 of 4.2 μM. P005091
  98. BCC1127 E 64d Aloxistatin (E64d) is a cell-permeable and irreversible broad-spectrum cysteine protease inhibitor. E 64d
  99. BCC2336 Ganetespib (STA-9090) Ganetespib is a heat shock protein 90 (HSP90) inhibitor which exhibits potent cytotoxicity in a wide variety of hematological and solid tumor cell lines. Ganetespib (STA-9090)
  100. BCC1992 Teneligliptin hydrobromide Teneligliptin (MP-513) hydrobromide is a potent chemotype prolylthiazolidine-based DPP-4 inhibitor, which competitively inhibits human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC50s of approximately 1 nM. Teneligliptin hydrobromide
  101. BCC2132 SNX-2112 SNX-2112 (PF-04928473) selectively binds to the ATP pocket of HSP90α and HSP90β with Ka of 30 nM and 30 nM, uniformly more potent than 17-AAG. SNX-2112

Items 101 to 200 of 217 total

     
  1. First
  2.  
  3.  
  4. 1
  5. 2
  6. 3
  7.  
  8.  
  9. Last